follistatin 344 vs cjc+ipa blend
updated
follistatin 344 (F-tier) vs cjc+ipa blend (A-tier). mechanism, trials, evidence boundaries, dosing literature. side-by-side reference.
follistatin 344 · tier F
myostatin biology is real. retail injectable follistatin-344 has zero human performance trials and major product-quality concerns.
myostatin biology is real. retail injectable follistatin-344 has zero human performance trials and well-documented product-quality problems.
myostatin 0 trials on the retail vial · half-life reported variable; reliable PK data in humans for performance doses is absent · growth hormone
cjc+ipa blend · tier A
clinic-standard GH-axis pairing. cjc-1295 + ipamorelin. receptor logic first, blend trial evidence still thin.
the most common peptide-clinic GH-axis stack. CJC-1295 + ipamorelin amplifies pulse amplitude through two separate receptors.
PCAC '24 503A excluded · half-life CJC-1295: 30 min (no DAC); ipamorelin: ~2 h · growth hormone
at a glance
- follistatin 344: tier F · myostatin 0 trials on the retail vial
- cjc+ipa blend: tier A · PCAC '24 503A excluded
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.